Physician profile
Michael Wilson
NPI 1164801411
$16,297.44
in general payments reported to CMS, 2019-2025
13 companies · $14K in 2025
The $14K reported for 2025 was more than what 97% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $440 · 2024: $1,855 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $2,650 · Travel and Lodging: $613 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,000.00 |
| Food and Beverage | $2,650.32 |
| Travel and Lodging | $613.12 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $13,182.06 | 2024-2025 | |
| Inspire Medical Systems, INC. | $1,809.85 | 2023-2025 | Inspire |
| Genzyme Corporation | $473.40 | 2023-2025 | |
| Amgen INC. | $209.63 | 2024-2025 | Tezspire, Tavneos |
| Regeneron Healthcare Solutions, INC. | $180.15 | 2023-2025 | Dupixent |
| Glaxosmithkline, LLC. | $155.53 | 2024-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $101.74 | 2024-2025 | Tezspire |
| Medtronic, INC. | $55.35 | 2024-2025 | Straightshot, Pteye Parathyroid Detection System |
| Smith+Nephew, INC. | $39.59 | 2023 | Halo, Tula |
| Innovation Technologies INC | $34.70 | 2025 | Irrisept |
| Grifols USA, LLC | $21.83 | 2024 | Prolastin-C Liquid |
| Kaleo, INC. | $17.61 | 2023 | Auvi-Q |
| 3b Medical, INC. | $16.00 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.